GSK plc (GSK) Stock Analysis and Metrics

Investment Thesis

▲ Bull case

GSK's long-acting HIV injectable portfolio is poised to capture significant market share gains through superior dosing convenience and strong real-world evidence, with Cabenuva already driving 75% of HIV growth in the quarter and Apretude showing competitive momentum in PrEP, positioning the company to maintain dominance in long-acting injectables for years ahead despite the Q4M delay, as the lack of competitors in this space creates a durable moat that will sustain pricing power and patient loyalty through 2030 and beyond, especially as VH184's best-in-class resistance profile and IP protection through 2040 ensure GSK remains the sole provider of ultra-long-acting regimens, making the HIV business a reliable cash cow that can fund other high-growth initiatives like oncology and respiratory without dilution risk.
The depemokimab launch in COPD represents a transformative opportunity with material upside potential, as only 27% of bio-naive eligible patients currently receive biologics and up to 65% discontinue therapy within 12 months due to adherence challenges, while depemokimab's 72% reduction in hospitalization with just twice-yearly dosing directly addresses this unmet need, supported by 86% of pulmonologists viewing it as a potential standard of care, and given GSK's proven ability to gain share in COPD with Nucala (from 0% to 46% of new patients against Dupixent), the asset is well-positioned to capture significant biologic-naive and switcher patients in a market with less than 5% current biologic penetration, making it a likely multi-blockbuster driver that could exceed current consensus estimates by a wide margin.
GSK's oncology pipeline is advancing with multiple near-term catalysts that are underappreciated by the market, including BLENREP's U.S. approval in third-line plus multiple myeloma showing a 51% reduction in death risk and tripling of median PFS versus daratumumab triplet, with over one-third of the 71,000 U.S. patients currently treated in this setting, and the simplified REMS program enabling community use where 70% of patients are treated, while GSK'981 for GIST and GSK'227 ADC in extensive stage small cell lung cancer are set to initiate pivotal trials by year-end, and Jemperli's ongoing rectal cancer trial (AZUR-1) expects readout in H2 2026 following transformative Phase II data showing 100% complete response rate, creating a clear pathway for multiple near-term data readouts that could re-rate the oncology franchise as a core growth engine rather than a niche player.
The company's $30 billion U.S. investment over five years in R&D and advanced manufacturing, including the new biologics flex factory in Pennsylvania, is a structural shift that will significantly enhance GSK's ability to scale production for complex biologics and ADCs, reduce supply chain constraints, and improve margins through localized production and operational efficiencies, yet this long-term capacity building initiative received minimal emphasis during the earnings call despite being critical to supporting the launch of 15 scale opportunities with >GBP 2 billion peak sales potential each before 2031, signaling that the market is underestimating GSK's commitment to de-risking its pipeline execution and building sustainable competitive advantage in manufacturing scale.
GSK's medium-term margin expansion is on track to deliver over 500 basis points of accretion between 2021 and 2026, driven by productivity gains from technology-enabled sales and marketing transformation, mix benefits from the continued shift to specialty medicines, and royalty income reinvestment into high-potency pipeline assets, with operating margin already at 33.9% year-to-date (up 100 bps at CER), and the company guiding to more than 31% by 2026, yet the market appears to be pricing in only incremental margin improvement despite clear evidence of operating leverage from SG&A efficiency gains and the scalability of the specialty portfolio, which continues to deliver double-digit growth across HIV, oncology, and RI&I while General Medicines remains stable, creating a clear path to sustained earnings growth that exceeds current consensus expectations.

GSK's long-acting HIV injectable portfolio is poised to capture significant market share gains through superior dosing convenience and strong real-world evidence, with Cabenuva already driving 75% of HIV growth in the quarter and Apretude showing competitive momentum in PrEP, positioning the company to maintain dominance in long-acting injectables for years ahead despite the Q4M delay, as the lack of competitors in this space creates a durable moat that will sustain pricing power and patient loyalty through 2030 and beyond, especially as VH184's best-in-class resistance profile and IP protection through 2040 ensure GSK remains the sole provider of ultra-long-acting regimens, making the HIV business a reliable cash cow that can fund other high-growth initiatives like oncology and respiratory without dilution risk.
The depemokimab launch in COPD represents a transformative opportunity with material upside potential, as only 27% of bio-naive eligible patients currently receive biologics and up to 65% discontinue therapy within 12 months due to adherence challenges, while depemokimab's 72% reduction in hospitalization with just twice-yearly dosing directly addresses this unmet need, supported by 86% of pulmonologists viewing it as a potential standard of care, and given GSK's proven ability to gain share in COPD with Nucala (from 0% to 46% of new patients against Dupixent), the asset is well-positioned to capture significant biologic-naive and switcher patients in a market with less than 5% current biologic penetration, making it a likely multi-blockbuster driver that could exceed current consensus estimates by a wide margin.
GSK's oncology pipeline is advancing with multiple near-term catalysts that are underappreciated by the market, including BLENREP's U.S. approval in third-line plus multiple myeloma showing a 51% reduction in death risk and tripling of median PFS versus daratumumab triplet, with over one-third of the 71,000 U.S. patients currently treated in this setting, and the simplified REMS program enabling community use where 70% of patients are treated, while GSK'981 for GIST and GSK'227 ADC in extensive stage small cell lung cancer are set to initiate pivotal trials by year-end, and Jemperli's ongoing rectal cancer trial (AZUR-1) expects readout in H2 2026 following transformative Phase II data showing 100% complete response rate, creating a clear pathway for multiple near-term data readouts that could re-rate the oncology franchise as a core growth engine rather than a niche player.
The company's $30 billion U.S. investment over five years in R&D and advanced manufacturing, including the new biologics flex factory in Pennsylvania, is a structural shift that will significantly enhance GSK's ability to scale production for complex biologics and ADCs, reduce supply chain constraints, and improve margins through localized production and operational efficiencies, yet this long-term capacity building initiative received minimal emphasis during the earnings call despite being critical to supporting the launch of 15 scale opportunities with >GBP 2 billion peak sales potential each before 2031, signaling that the market is underestimating GSK's commitment to de-risking its pipeline execution and building sustainable competitive advantage in manufacturing scale.
GSK's medium-term margin expansion is on track to deliver over 500 basis points of accretion between 2021 and 2026, driven by productivity gains from technology-enabled sales and marketing transformation, mix benefits from the continued shift to specialty medicines, and royalty income reinvestment into high-potency pipeline assets, with operating margin already at 33.9% year-to-date (up 100 bps at CER), and the company guiding to more than 31% by 2026, yet the market appears to be pricing in only incremental margin improvement despite clear evidence of operating leverage from SG&A efficiency gains and the scalability of the specialty portfolio, which continues to deliver double-digit growth across HIV, oncology, and RI&I while General Medicines remains stable, creating a clear path to sustained earnings growth that exceeds current consensus expectations.

▼ Bear case

GSK's HIV long-acting pipeline faces growing competitive threats from oral regimens like Gilead's weekly oral lenacapavir plus islatravir, which, despite clinical hold on the integrase inhibitor component, could still launch in 2027 and offer a more convenient dosing option that may erode the value proposition of injectables, especially as patient preference data shows only 15% willingness for Q2M, 30% for Q4M, and 50% for Q6M regimens, indicating that even with superior dosing intervals, a significant portion of the patient base may prefer oral alternatives, and with islatravir's history of safety concerns and the competitor's prodrug of lenacapavir plus integrase inhibitor on clinical hold, the near-term threat may be limited, but the long-term risk to GSK's ultra-long-acting franchise remains real if oral options gain traction due to lower burden of administration and avoidance of injection-related discomfort.
The depemokimab launch in COPD is subject to significant execution risk, as the company's own data shows that only 27% of bio-naive eligible patients currently receive biologics and up to 65% discontinue therapy within 12 months due to adherence challenges, and while depemokimab's twice-yearly dosing aims to solve this, there is no guarantee that pulmonologists will adopt it rapidly given the entrenched use of existing biologics like Dupixent and Fasenra, especially since GSK acknowledged that prescribers only use Nucala in 1 in 3 COPD patients for various reasons, and the company's reliance on market research showing 86% pulmonologist support may not translate to real-world prescribing behavior, particularly in a cost-sensitive environment where payers may favor established therapies with longer safety records over a new agent with limited real-world evidence at launch.
BLENREP's growth potential is constrained by its narrow initial U.S. label in third-line plus multiple myeloma, which limits the addressable patient pool to approximately one-third of the 71,000 currently treated patients, and while the company plans to expand to earlier lines, the path to second line requires successful pivotal trials and FDA approval, a process that historically takes 3-4 years, and the material growth driver expectations of 3-4 years may be overly optimistic given the need to build clinical experience, navigate REMS (even with the simplified version), and convince community oncologists to adopt a novel mechanism of action in a setting where 70% of patients are treated, all while facing entrenched competition from CAR-T therapies and other BCMA-targeted agents that may offer superior efficacy or convenience, making it unlikely that BLENREP will reach peak sales potential before 2029-2030, well beyond the near-term horizon.
GSK's Vaccines business continues to face structural headwinds in the U.S., with Shingrix penetration at only 43% of the eligible older adult population and immunization rates slowing as expected due to harder-to-reach populations, Arexvy declining due to lower preseason channel inventory build and slower market uptake in the 60-plus population, and flu vaccines under competitive pressure from younger cohort-focused alternatives, while the company's guidance assumes only declining low single digit to stable performance, yet the market may be underestimating the persistent drag from generic competition in Established Vaccines and the lack of meaningful new vaccine launches beyond Shingrix, Arexvy, and Bexsero, leaving the franchise vulnerable to prolonged stagnation that could weigh on overall growth and divert resources from higher-potential specialty assets.
The company's reliance on business development as a key driver of pipeline expansion introduces valuation and execution risk, as recent deals like efimosfermin for MASH and GSK'981 for GIST, while promising, are still in early-to-mid stage development with pivotal trials only now initiating or planned, and the success of these assets is far from guaranteed, especially given the high failure rates in metabolic disease and oncology clinical trials, yet GSK's guidance and long-term outlook assume these BD-sourced assets will contribute meaningfully to the 15 scale opportunities with >GBP 2 billion peak sales potential, creating a scenario where failure to advance even a few of these candidates could significantly undermine the credibility of the long-term financial targets, particularly as the company has already upgraded its 2031 revenue target twice based on pipeline assumptions that may not materialize as expected.

GSK's HIV long-acting pipeline faces growing competitive threats from oral regimens like Gilead's weekly oral lenacapavir plus islatravir, which, despite clinical hold on the integrase inhibitor component, could still launch in 2027 and offer a more convenient dosing option that may erode the value proposition of injectables, especially as patient preference data shows only 15% willingness for Q2M, 30% for Q4M, and 50% for Q6M regimens, indicating that even with superior dosing intervals, a significant portion of the patient base may prefer oral alternatives, and with islatravir's history of safety concerns and the competitor's prodrug of lenacapavir plus integrase inhibitor on clinical hold, the near-term threat may be limited, but the long-term risk to GSK's ultra-long-acting franchise remains real if oral options gain traction due to lower burden of administration and avoidance of injection-related discomfort.
The depemokimab launch in COPD is subject to significant execution risk, as the company's own data shows that only 27% of bio-naive eligible patients currently receive biologics and up to 65% discontinue therapy within 12 months due to adherence challenges, and while depemokimab's twice-yearly dosing aims to solve this, there is no guarantee that pulmonologists will adopt it rapidly given the entrenched use of existing biologics like Dupixent and Fasenra, especially since GSK acknowledged that prescribers only use Nucala in 1 in 3 COPD patients for various reasons, and the company's reliance on market research showing 86% pulmonologist support may not translate to real-world prescribing behavior, particularly in a cost-sensitive environment where payers may favor established therapies with longer safety records over a new agent with limited real-world evidence at launch.
BLENREP's growth potential is constrained by its narrow initial U.S. label in third-line plus multiple myeloma, which limits the addressable patient pool to approximately one-third of the 71,000 currently treated patients, and while the company plans to expand to earlier lines, the path to second line requires successful pivotal trials and FDA approval, a process that historically takes 3-4 years, and the material growth driver expectations of 3-4 years may be overly optimistic given the need to build clinical experience, navigate REMS (even with the simplified version), and convince community oncologists to adopt a novel mechanism of action in a setting where 70% of patients are treated, all while facing entrenched competition from CAR-T therapies and other BCMA-targeted agents that may offer superior efficacy or convenience, making it unlikely that BLENREP will reach peak sales potential before 2029-2030, well beyond the near-term horizon.
GSK's Vaccines business continues to face structural headwinds in the U.S., with Shingrix penetration at only 43% of the eligible older adult population and immunization rates slowing as expected due to harder-to-reach populations, Arexvy declining due to lower preseason channel inventory build and slower market uptake in the 60-plus population, and flu vaccines under competitive pressure from younger cohort-focused alternatives, while the company's guidance assumes only declining low single digit to stable performance, yet the market may be underestimating the persistent drag from generic competition in Established Vaccines and the lack of meaningful new vaccine launches beyond Shingrix, Arexvy, and Bexsero, leaving the franchise vulnerable to prolonged stagnation that could weigh on overall growth and divert resources from higher-potential specialty assets.
The company's reliance on business development as a key driver of pipeline expansion introduces valuation and execution risk, as recent deals like efimosfermin for MASH and GSK'981 for GIST, while promising, are still in early-to-mid stage development with pivotal trials only now initiating or planned, and the success of these assets is far from guaranteed, especially given the high failure rates in metabolic disease and oncology clinical trials, yet GSK's guidance and long-term outlook assume these BD-sourced assets will contribute meaningfully to the 15 scale opportunities with >GBP 2 billion peak sales potential, creating a scenario where failure to advance even a few of these candidates could significantly undermine the credibility of the long-term financial targets, particularly as the company has already upgraded its 2031 revenue target twice based on pipeline assumptions that may not materialize as expected.

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	JNJ	Johnson & Johnson	645.88 Bn	30.70	6.60	49.04 Bn
2	ABBV	AbbVie Inc.	463.46 Bn	73.38	7.20	70.82 Bn
3	MRK	Merck & Co., Inc.	367.92 Bn	116.10	5.53	53.91 Bn
4	NVS	Novartis Ag	297.71 Bn	90.41	19.47	9.59 Bn
5	AZN	Astrazeneca Plc	255.55 Bn	23.38	4.16	29.49 Bn
6	AMGN	Amgen Inc	234.52 Bn	26.82	6.16	62.75 Bn
7	GILD	Gilead Sciences, Inc.	178.22 Bn	-61.56	5.85	28.66 Bn
8	PFE	Pfizer Inc	158.57 Bn	36.30	2.49	63.19 Bn

Research Tools

Datasets

Plans

Developers

Gsk GSK

About

Investment Thesis

Products and services [axis] Breakdown of Revenue (2025)

Geographical areas [axis] Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Datasets

Plans

Developers

Gsk GSK

About

Investment Thesis

Products and services [axis] Breakdown of Revenue (2025)

Geographical areas [axis] Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password